Related Experiment Video
Updated: Aug 8, 2026

Author Spotlight: A 3D Digital Model for the Diagnosis and Treatment of Pulmonary Nodules
Published on: May 19, 2023
ScreenDx, an artificial intelligence-based algorithm for the incidental detection of pulmonary fibrosis
Nikolas Touloumes1, Georgia Gagianas2, James Bradley3
1Division of General Internal Medicine, Dept. of Medicine, University of Louisville. 550 South Jackson Street, 3rd Floor, Ste A3K00, Louisville, KY 40202, United States.
Background:
Nonspecific symptoms and variability in radiographic reporting patterns contribute to a diagnostic delay of the diagnosis of pulmonary fibrosis. An attractive solution is the use of machine-learning algorithms to screen for radiographic features suggestive of pulmonary fibrosis. Thus, we developed and validated a machine learning classifier algorithm (ScreenDx) to screen computed tomography imaging and identify incidental cases of pulmonary fibrosis.
Methods:
ScreenDx is a deep learning convolutional neural network that was developed from a multi-source dataset (cohort A) of 3,658 cases of normal and abnormal CT's, including CT's from patients with COPD, emphysema, and community-acquired pneumonia. Cohort B, a US-based cohort (n = 381) was used for tuning the algorithm, and external validation was performed on cohort C (n = 683), a separate international dataset.
Results:
At the optimal threshold, the sensitivity and specificity for detection of pulmonary fibrosis in cohort B was 0.91 (95 % CI 88-94 %) and 0.95 (95 % CI 93-97 %), respectively, with AUC 0.98. In the external validation dataset (cohort C), the sensitivity and specificity were 1.0 (95 % 99.9-100.0) and 0.98 (95 % CI 97.9-99.6), respectively, with AUC 0.997. There were no significant differences in the ability of ScreenDx to identify pulmonary fibrosis based on CT manufacturer (Phillips, Toshiba, GE Healthcare, or Siemens) or slice thickness (2 mm vs 2-4 mm vs 4 mm).
Conclusion:
Regardless of CT manufacturer or slice thickness, ScreenDx demonstrated high performance across two, multi-site datasets for identifying incidental cases of pulmonary fibrosis. This suggest that the algorithm may be generalizable across patient populations and different healthcare systems.

